These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 16823934

  • 1. Mucosal immune responses to meningococcal C polysaccharide-protein conjugate in mice.
    Cuello M, Cabrera O, del Campo JM, Parajón E, Sotolongo F, Camaraza MA, Arnet A, Suárez M, Pérez O.
    Vaccine; 2006 Apr 12; 24 Suppl 2():S2-72-3. PubMed ID: 16823934
    [Abstract] [Full Text] [Related]

  • 2. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
    Cuello M, Cabrera O, Martinez I, Del Campo JM, Camaraza MA, Sotolongo F, Pérez O, Sierra G.
    Vaccine; 2007 Feb 26; 25(10):1798-805. PubMed ID: 17240485
    [Abstract] [Full Text] [Related]

  • 3. Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants.
    Zhang Q, Pettitt E, Burkinshaw R, Race G, Shaw L, Finn A.
    Pediatr Infect Dis J; 2002 Mar 26; 21(3):209-13. PubMed ID: 12005084
    [Abstract] [Full Text] [Related]

  • 4. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine.
    Zhang T, Yu W, Wang Y, Hu T.
    Vaccine; 2015 Jun 22; 33(28):3208-14. PubMed ID: 25964170
    [Abstract] [Full Text] [Related]

  • 5. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents.
    Zhang Q, Choo S, Everard J, Jennings R, Finn A.
    Infect Immun; 2000 May 22; 68(5):2692-7. PubMed ID: 10768961
    [Abstract] [Full Text] [Related]

  • 6. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q, Lakshman R, Burkinshaw R, Choo S, Everard J, Akhtar S, Finn A.
    Infect Immun; 2001 Jul 22; 69(7):4337-41. PubMed ID: 11401971
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains.
    Richmond P, Borrow R, Findlow J, Martin S, Thornton C, Cartwright K, Miller E.
    Infect Immun; 2001 Apr 22; 69(4):2378-82. PubMed ID: 11254596
    [Abstract] [Full Text] [Related]

  • 8. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine.
    Qiao W, Ji S, Zhao Y, Hu T.
    Vaccine; 2015 Apr 21; 33(17):2066-72. PubMed ID: 25728319
    [Abstract] [Full Text] [Related]

  • 9. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
    Stoof SP, van der Klis FR, van Rooijen DM, Bogaert D, Trzciński K, Sanders EA, Berbers GA.
    Vaccine; 2015 Jul 31; 33(32):3933-9. PubMed ID: 26100925
    [Abstract] [Full Text] [Related]

  • 10. Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.
    Rubinstein LJ, García-Ojeda PA, Michon F, Jennings HJ, Stein KE.
    Infect Immun; 1998 Nov 31; 66(11):5450-6. PubMed ID: 9784556
    [Abstract] [Full Text] [Related]

  • 11. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
    Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J.
    Vaccine; 2000 Nov 22; 19(7-8):850-61. PubMed ID: 11115709
    [Abstract] [Full Text] [Related]

  • 12. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Knol MJ, Stoof SP, Sanders EAM, Berbers GAM.
    Vaccine; 2017 Aug 24; 35(36):4745-4752. PubMed ID: 28668575
    [Abstract] [Full Text] [Related]

  • 13. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, Boutriau D, HibMenCY-TT 005 Study Group.
    Pediatr Infect Dis J; 2010 Jan 24; 29(1):48-52. PubMed ID: 20035207
    [Abstract] [Full Text] [Related]

  • 14. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
    Southern J, Deane S, Ashton L, Borrow R, Goldblatt D, Andrews N, Balmer P, Morris R, Kroll JS, Miller E.
    Clin Diagn Lab Immunol; 2004 Nov 24; 11(6):1100-4. PubMed ID: 15539513
    [Abstract] [Full Text] [Related]

  • 15. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
    Marshall GS, Marchant CD, Blatter M, Friedland LR, Aris E, Miller JM.
    Hum Vaccin; 2011 Feb 24; 7(2):258-64. PubMed ID: 21307655
    [Abstract] [Full Text] [Related]

  • 16. Conjugation of Meningococcal Lipooligosaccharides Through Their Non-Reducing Terminus Results in Improved Induction a Protective Immune Response.
    Mieszała M, Jennings HJ, Drab M, Gamian A.
    Arch Immunol Ther Exp (Warsz); 2019 Aug 24; 67(4):237-248. PubMed ID: 31030218
    [Abstract] [Full Text] [Related]

  • 17. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB, den Hartog G, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    PLoS One; 2018 Aug 24; 13(4):e0191261. PubMed ID: 29672552
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP, Habanec T, Kosina P, Shah NR, Kolhe D, Miller JM, Hezareh M, Van der Wielen M.
    Vaccine; 2018 Apr 19; 36(17):2356-2363. PubMed ID: 29576307
    [Abstract] [Full Text] [Related]

  • 19. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
    Yasuda Y, Isaka M, Taniguchi T, Zhao Y, Matano K, Matsui H, Morokuma K, Maeyama J, Ohkuma K, Goto N, Tochikubo K.
    Vaccine; 2003 Jun 20; 21(21-22):2954-63. PubMed ID: 12798639
    [Abstract] [Full Text] [Related]

  • 20. Development and Immunogenicity of a Brazilian Glycoconjugate vaccine against Meningococcal W in a Pilot Scale.
    de Souza IM, da Silva MN, Bastos RC, Pereira DDSG, Figueira ECS, Jessouroun E, Leal MLM, Barreto-Bergter E, da Silveira IAFB.
    Glycoconj J; 2021 Oct 20; 38(5):539-549. PubMed ID: 34515909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.